Semaglutide: The Evidence on Fat Loss, Muscle Loss, and Everything in Between

Verdict

What Is Semaglutide?

Semaglutide is a synthetic peptide that mimics GLP-1 — a hormone your gut naturally produces after eating. Native GLP-1 has one job: signal the brain and pancreas that food has arrived, insulin should be released, and appetite should taper off.

The problem with native GLP-1 is that an enzyme called DPP-4 destroys it within two minutes of release. It barely lasts long enough to do its job.

Semaglutide fixes this with two structural modifications. One blocks DPP-4 from cleaving the peptide. The other attaches a fatty acid chain that binds to albumin (a blood protein), creating a slow-release reservoir. The result: a half-life of about seven days, meaning one injection per week keeps GLP-1 receptors continuously activated — a state the body never reaches naturally.

GLP-1 Receptor Agonist Generations

Semaglutide is not the first GLP-1 receptor agonist, and it will not be the last. Knowing where it sits in the landscape matters for anyone weighing options.

Each generation adds receptor targets. Semaglutide hits GLP-1 receptors only. Tirzepatide hits both GLP-1 and GIP receptors, producing about 20-22% weight loss at the highest studied dose.^[12]

Retatrutide adds glucagon receptor activation on top of those two, producing about 24% weight loss in Phase II data at 48 weeks.^[13] More targets does not automatically mean better — it means different tradeoffs.

Mechanism of Action: How GLP-1 Receptor Agonism Works

GLP-1 receptors are not confined to one organ. They exist in the pancreas, brain, gut, liver, and cardiovascular system.^[17] That is why semaglutide does much more than suppress appetite — it reshapes how the entire body handles energy, food signaling, and glucose metabolism.

Here is how each pathway contributes to the overall effect.

Clinical Research — The STEP Trial Program

The STEP program (Semaglutide Treatment Effect in People with Obesity) is one of the most comprehensive clinical trial programs ever run for a weight management drug. Multiple Phase III, double-blind, placebo-controlled trials. Thousands of participants. Different populations and study designs.

Here is what each trial found.

STEP 1 — The Landmark Obesity Trial

This is the trial that changed the conversation. 1,961 adults with BMI of 30 or above (or 27+ with a comorbidity), without diabetes, were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Both groups got lifestyle counseling.^[1]

The results were striking. The semaglutide group lost an average of 14.9% of body weight, versus 2.4% for placebo. That is a 12.5 percentage point difference — unprecedented for a pharmaceutical.

Among semaglutide-treated participants, 86.4% lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost 15% or more.

The DEXA body composition substudy revealed the number that matters most for physique-focused readers: about 8.4 kg of fat mass was lost alongside 5.3 kg of lean mass. Lean mass accounted for roughly 39% of total weight lost. That ratio becomes central to the muscle loss discussion below.

STEP 2 — Type 2 Diabetes Population

STEP 2 enrolled 1,210 adults with type 2 diabetes and BMI of 27 or above. At 68 weeks, the semaglutide group lost 9.6% of body weight versus 3.4% for placebo.^[2]

The lower weight loss compared to STEP 1 is notable — and consistent across the GLP-1 receptor agonist class. Type 2 diabetes seems to blunt the weight loss response. The likely reason: insulin resistance itself changes how the body partitions energy, and the metabolic derangement of established diabetes reduces the appetite-suppressive effect.

HbA1c (a marker of average blood sugar over ~3 months) dropped by 1.6 percentage points from a baseline of around 8.1% — a clinically significant improvement in glycemic control.

STEP 3 — Adding Intensive Behavioral Therapy

When semaglutide was combined with intensive behavioral therapy (structured diet counseling, meal replacements, more physical activity), weight loss jumped to 16.0% versus 5.7% for placebo plus the same behavioral program.^[3] That confirms an additive benefit: the drug works better when paired with structured lifestyle changes.

STEP 4 — The Discontinuation Study

This may be the most important trial for anyone thinking about semaglutide for physique purposes.

All participants got semaglutide for 20 weeks. Then half were randomized to continue, while the other half switched to placebo for 48 more weeks.^[4]

The continuation group lost a further 7.9% body weight (total: about 17.4%). The withdrawal group regained 6.9% — clawing back roughly two-thirds of the weight lost during the first 20 weeks.

STEP 5 — Two-Year Data

STEP 5 extended observation to 104 weeks — two full years. Weight loss was maintained at about 15.2%, with a plateau around weeks 60-68.^[5]

Long-term tolerability was confirmed. The weight does not keep dropping forever — a new equilibrium gets established, and the body stabilizes at a lower set point as long as treatment continues.

STEP 8 — Head-to-Head vs. Liraglutide

This trial answered the direct comparison question. Semaglutide 2.4 mg weekly produced 15.8% weight loss versus 6.4% for liraglutide 3.0 mg daily.^[6]

Semaglutide produced about 2.5 times greater weight loss than the previous-generation GLP-1 receptor agonist. The improvement is not marginal — it is a categorical leap.

The Muscle Loss Problem

This section is the reason this article exists. Fat loss is well-documented. What happens to muscle is the question the enhancement community actually needs answered.

What the STEP Trials Found

The STEP 1 DEXA substudy measured body composition directly. Of the total weight lost, about 61% was fat mass (~8.4 kg) and 39% was lean mass (~5.3 kg).^[1]

Before reacting to that number, context matters. A roughly 60:40 fat-to-lean loss ratio is actually consistent with caloric restriction at this magnitude in general. Diet-only studies without resistance training show similar or worse ratios.^[10]

Meta-analyses of GLP-1 receptor agonists as a class find no unique muscle-wasting mechanism — the lean mass loss is proportional to total weight loss.^[11] In other words, semaglutide does not cause special damage to muscle tissue.

The problem is different. The weight loss is so large that even a normal ratio translates to significant absolute lean mass loss. For a 100 kg individual losing 15 kg, about 6 kg of that is lean tissue. That is a meaningful amount to lose from the non-fat compartment.

Lean Mass vs. Muscle Mass — An Important Distinction

"Lean mass" on a DEXA scan includes everything that is not fat or bone mineral. That means skeletal muscle, but also organ tissue, connective tissue, water, and glycogen (stored carbohydrate in muscle).

This distinction matters. A significant portion of "lean mass loss" during caloric restriction is actually intracellular water and glycogen depletion from eating less — not true contractile muscle protein disappearing.

Actual skeletal muscle protein loss is still happening — just not at the full magnitude that raw lean mass numbers suggest. No STEP trial used more precise measurement methods (like D3-creatine dilution, which specifically measures contractile protein) to separate real muscle loss from water and glycogen shifts. That is a measurement limitation, not an exoneration.

Can Resistance Training Mitigate the Loss?

The STEP 1-5 trials included "lifestyle counseling" but did not mandate structured resistance training programs. The participants were untrained, overweight or obese adults.

That means the lean mass loss data reflects what happens when sedentary people lose large amounts of weight through appetite suppression alone — without the protective stimulus of lifting weights.

A study of liraglutide (the previous-generation GLP-1 receptor agonist) combined with structured exercise found the combination preserved more lean mass than liraglutide alone — but did not fully eliminate lean mass loss.^[9] The combination group lost mostly fat mass with minimal lean mass reduction.

General caloric restriction literature is clearer on this point. Resistance training during caloric restriction preserves roughly 50-100% more lean mass than caloric restriction alone. High protein intake (1.2-1.6 g/kg/day or above) further improves preservation.

The combination of resistance training plus high protein during caloric restriction can shift the fat-to-lean loss ratio from roughly 60:40 to about 80:20 or better.^[10]

Myostatin Inhibitor Combinations — Speculative

Trevogrumab and bimagrumab — both of which block the myostatin/activin pathway (the body's natural brake on muscle growth) — are being studied in combination with semaglutide to preserve lean mass during GLP-1 RA-induced weight loss.

Trials are registered but results have not been published as of early 2026. The enhancement community has taken strong interest in anti-myostatin agents as a fix, though this currently sits firmly in the speculative category with no published efficacy data for this specific application.

Cardiovascular Outcomes — The SELECT Trial

SELECT is the trial that moved semaglutide from a weight loss drug to a cardiovascular risk reduction tool.

17,604 adults aged 45 and older, with BMI of 27 or above, established cardiovascular disease, and without diabetes, were randomized to semaglutide 2.4 mg weekly or placebo. Mean follow-up was 39.8 months — over three years.^[7]

The primary endpoint was MACE — a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. Semaglutide reduced MACE by 20% (hazard ratio 0.80, 95% CI 0.72-0.90, p < 0.001). Nonfatal heart attack specifically dropped by 28%.

All-cause mortality trended lower (HR 0.81) but did not reach individual statistical significance. This was the first trial to show cardiovascular benefit of a GLP-1 receptor agonist in a non-diabetic obese population. Previously, the SUSTAIN-6 trial had shown cardiovascular benefit only in patients with type 2 diabetes.^[8]

The cardiovascular data goes beyond SELECT. The STEP-HFpEF trial showed improvement in heart failure symptoms and physical limitations in obese patients with heart failure with preserved ejection fraction — the most common and hardest-to-treat form of heart failure.^[15]

Semaglutide has also shown benefit in nonalcoholic steatohepatitis (NASH/MASH) — fatty liver disease that has progressed to active inflammation. Treatment reduced liver inflammation and fibrosis in a placebo-controlled trial.^[16]

Common Questions — Dosing, Safety, Comparisons

How Semaglutide Compares to Other GLP-1 RAs

Semaglutide 2.4 mg weekly produces about 2.5 times the weight loss of liraglutide 3.0 mg daily — a decisive step forward shown in the head-to-head STEP 8 trial.^[6]

Tirzepatide (Mounjaro/Zepbound), the dual GLP-1/GIP receptor agonist, produces about 20-22% weight loss at 15 mg weekly in the SURMOUNT trials — roughly 5-7 percentage points more than semaglutide at its maximum studied dose.^[12]

Retatrutide, the triple receptor agonist currently in Phase III, produced about 24% weight loss in Phase II at 48 weeks.^[13]

More weight loss is not automatically better. The body composition question — how much of that additional weight loss comes from fat versus lean tissue — becomes increasingly critical as total weight loss magnitude rises.

Weight Regain After Discontinuation

The STEP 4 withdrawal data is unambiguous: participants who stopped semaglutide regained about two-thirds of the weight lost within 48 weeks.^[4]

Appetite suppression needs ongoing GLP-1 receptor activation. Once discontinued, baseline appetite physiology returns — and for many people, the rebound appetite is described as aggressive, with rapid fat accumulation that can exceed pre-treatment levels in some cases.

The clinical interpretation is straightforward: semaglutide does not reset appetite set points. It overrides them for as long as the compound is present. Discontinuation without a structured transition plan leads to predictable rebound.

For physique competitors who might consider time-limited use for contest preparation, weight regain is a near-certainty without meticulous reverse dieting.

Gastrointestinal Side Effects

GI side effects are the most common adverse events and the main reason people discontinue treatment.^[1]

Most GI effects are transient and dose-dependent. Slow dose escalation substantially reduces severity. Treat the first few weeks on the compound as an adaptation phase, not a period to push for maximum weight loss.

Rapid dose escalation has led to emergency room visits from uncontrollable vomiting and inability to hydrate. Electrolyte depletion from vomiting and diarrhea is a genuine concern during the titration phase.

For electrolyte management strategies and magnesium supplementation during GI disturbance, see the respective analyses.

Thyroid Cancer Signal

Rodent studies found that semaglutide (and other GLP-1 receptor agonists) caused thyroid C-cell tumors in rats and mice at clinically relevant exposures. In humans, no confirmed increased risk has been established.

The FDA still requires a boxed warning — the most serious type — citing the rodent findings. Semaglutide is contraindicated in anyone with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

For perspective, MTC accounts for only 1-2% of all thyroid cancers. Human epidemiological data accumulated since GLP-1 receptor agonists were approved has not confirmed the rodent signal, but surveillance is ongoing.

Pancreatitis Risk

Acute pancreatitis has been reported across the GLP-1 receptor agonist class, though it is rare. Meta-analyses suggest no statistically significant increased risk with semaglutide specifically. Caution is warranted in anyone with a history of pancreatitis.

Risk Profile Analysis

Established Risks (Tier 1 Evidence)

• GI adverse events: Nausea, vomiting, diarrhea, constipation — 40-50% incidence at full dose, mostly transient and dose-dependent
• Gallbladder events: Cholelithiasis and cholecystitis incidence is increased with rapid weight loss (consistent with any rapid weight loss intervention, not semaglutide-specific)
• Acute kidney injury: Rare; primarily secondary to dehydration from severe GI side effects
• Resting heart rate increase: Small increase of approximately 2-4 bpm observed across trials
• Weight regain after discontinuation: Rapid and substantial — approximately two-thirds of weight lost is regained within one year of stopping
• Injection site reactions: Mild, infrequent

Theoretical or Uncertain Risks

• Thyroid C-cell tumors: Confirmed in rodents, not confirmed in humans; FDA boxed warning
• Pancreatitis: Rare reports across GLP-1 RA class; meta-analyses not statistically significant
• Bone mineral density: Insufficiently studied during prolonged use and large weight loss
• Long-term effects beyond 2 years: Data still accumulating; STEP 5 provides the longest controlled observation at 104 weeks

Contraindications

Evidence Synthesis

What Is Established

1. Semaglutide 2.4 mg weekly produces ~15% body weight loss over 68 weeks in non-diabetic overweight/obese adults^[1]
2. Approximately 40% of weight lost is lean mass, consistent with caloric restriction generally^[1]
3. Cardiovascular outcomes improve — 20% MACE reduction in non-diabetic obese adults with established CVD^[7]
4. Weight regain is rapid upon discontinuation — ~2/3 regained within one year^[4]
5. GI side effects are common but mostly transient and dose-dependent^[1]
6. Insulin sensitivity and glycemic control improve significantly^[2]
7. Semaglutide is more effective than liraglutide — approximately 2.5x greater weight loss^[6]
8. Tirzepatide produces greater weight loss than semaglutide at maximum studied doses^[12]

What Is Not Established

1. Whether resistance training fully mitigates lean mass loss on semaglutide — no semaglutide + structured RT trial exists
2. Body composition beyond DEXA — actual skeletal muscle protein quantification has not been performed
3. Effects in already-lean or trained individuals — all data is from populations with BMI 27-30+
4. Interaction with anabolic compounds — no data on AAS, SARMs, growth hormone, or exogenous insulin combinations
5. Optimal protein intake during treatment — general CR data is extrapolated, not directly studied
6. Long-term bone mineral density effects during prolonged use
7. Neurotransmitter system effects — dopamine, serotonin modulation during chronic use is poorly characterized
8. Addiction modulation — emerging anecdotal data, no controlled trials

For Physique Enhancement

The Enhancement Community Context

GLP-1 receptor agonists are widely used in the bodybuilding and physique enhancement community, primarily during cutting phases. The appeal is straightforward:

• Appetite suppression that makes severe caloric restriction manageable
• Improved insulin sensitivity during both cutting and bulking
• A hemodynamic profile that is dramatically gentler than stimulatory fat burners

The concern is not whether semaglutide works for fat loss — it clearly does. The concern is whether the body composition tradeoff is acceptable when muscle mass is the primary asset being protected.

During a Cutting Phase

The appetite suppression eliminates "food noise" and dramatically improves diet adherence during long caloric deficits. The gastric emptying delay means smaller meals produce greater and longer satiety.

For people used to white-knuckling through caloric restriction, GLP-1 receptor agonists are a fundamentally different experience — appetite management rather than appetite endurance.

The lean mass loss concern is amplified in people carrying a lot more muscle mass than the STEP trial populations. Those trials enrolled untrained, overweight/obese adults. No clinical trial has studied semaglutide in resistance-trained, lean individuals.

All body composition data comes from populations with BMI of 27-30 or higher. Extrapolation from there to a trained individual at 12% body fat is uncertain at best.

Interaction with Anabolic Compounds

Anabolic-androgenic steroids provide anti-catabolic effect through androgen receptor activation, which may theoretically counteract the lean mass loss seen with GLP-1 receptor agonists. Growth hormone promotes fat breakdown and lean mass preservation through mechanisms that are complementary to semaglutide's appetite suppression.

These theoretical synergies are plausible but entirely unvalidated.

One critical interaction stands out: semaglutide reduces insulin secretion and improves insulin sensitivity. For anyone using exogenous insulin, that creates a genuine hypoglycemia risk if insulin dosing is not adjusted downward. This is not theoretical — it is a pharmacologically predictable interaction.

Observations from the enhancement community suggest many people combine GLP-1 receptor agonists with anabolic compounds during cutting phases and report favorable outcomes — mostly fat loss with minimal muscle loss. These are uncontrolled observations with massive confounding.

Those individuals are simultaneously training, eating high protein, and often using multiple compounds. Attributing outcomes specifically to the GLP-1 receptor agonist is not possible.

For context on the compounds referenced above, see the testosterone analysis, nandrolone analysis, and first cycle guide.

The "Flat" Problem

Users in the enhancement community report that GLP-1 receptor agonists can cause a "flat" appearance — less muscle fullness and vascularity.

The mechanism is indirect: less food intake means less carbohydrate intake, which means less glycogen storage in skeletal muscle, which decreases muscle volume. Less glycogen means less intracellular water, and the muscle looks deflated.

This is not a direct pharmacological effect on muscle glycogen. Once glycogen is stored in skeletal muscle, it stays there until burned through activity. Semaglutide does not deplete existing stores. It suppresses the appetite that drives carbohydrate consumption, which reduces glycogen replenishment over time.

The fix is deliberate carbohydrate manipulation — strategic carb intake timed around training to meet glycogen replenishment needs. Semaglutide does not block carbohydrate loading. It reduces the spontaneous desire to eat. Electrolyte depletion from GI side effects may also contribute to the flat appearance.

Semaglutide vs. Stimulatory Fat Burners

Traditional cutting pharmacology — ephedrine, clenbuterol, DNP, T3 — raises heart rate and sympathetic nervous system activity. Semaglutide's heart rate increase is mild (about 2-4 bpm) compared to stimulatory agents.

Semaglutide does not directly increase metabolic rate or energy expenditure. It works through appetite suppression and improved metabolic partitioning — a fundamentally different mechanism from thermogenics.

For people already managing cardiovascular load from anabolic compounds, semaglutide's hemodynamic profile may be preferable to stimulants. The tradeoff is cost: GLP-1 receptor agonists are substantially more expensive than traditional cutting agents.

Related protocols that may complement a GLP-1 RA approach include the metabolic AMPK protocol (berberine, omega-3, CoQ10, creatine) and the joint and connective tissue protocol for joint support during rapid weight loss. For an entirely different mechanism of action in the exercise mimetic space, see the SLU-PP-332 analysis.

For Cognitive Enhancement

GLP-1 receptors are not just in the gut and pancreas. They exist throughout the central nervous system — including the hippocampus (memory), cortex (higher-order thinking), and brainstem nuclei (basic survival functions). That distribution has triggered research into whether GLP-1 receptor agonists have neuroprotective properties beyond their metabolic effects.

The most advanced evidence comes from exenatide (the first-generation GLP-1 receptor agonist), which has been studied in Parkinson's disease. A randomized, placebo-controlled trial showed exenatide slowed motor function decline over 48 weeks.^[14]

Semaglutide is currently being evaluated in the EVOKE and EVOKE+ trials for Alzheimer's disease, though results are not yet available.

The indirect cognitive benefit pathway is more established. Insulin resistance is increasingly linked to cognitive decline and dementia risk — so much so that Alzheimer's disease is sometimes informally called "type 3 diabetes." By improving glycemic control and reducing the neuroinflammation associated with metabolic syndrome, semaglutide may reduce long-term cognitive risk through metabolic normalization rather than direct neuroprotection.

The Addiction Angle

Anecdotal reports of reduced addictive behavior — food addiction, alcohol consumption, gambling — on GLP-1 receptor agonists have attracted significant attention.

The hypothesized mechanism: GLP-1 receptors in the brain's reward centers may modulate the dopamine signaling that drives addictive patterns. The serotonin and dopaminergic effects of semaglutide remain poorly understood, and these observations have not been confirmed in controlled trials.

Importantly, these behavioral changes appear to require ongoing treatment — discontinuation may lead to return of previous patterns.

No cognitive enhancement claims can be made based on current evidence. This is a research frontier, not an established application.

Conclusions

Semaglutide is the most extensively studied weight loss drug in modern pharmaceutical history. The STEP trial program and SELECT cardiovascular outcomes trial provide Tier 1 evidence that this compound produces meaningful fat loss — 14.9% average body weight reduction — and reduces cardiovascular events in obese populations.^[1],[7]

The main concern for physique-focused people — lean mass loss — is real but nuanced. The roughly 40% lean mass fraction of total weight lost is consistent with caloric restriction in general, not a unique pharmacological assault on muscle tissue.

Resistance training and high protein intake are expected to substantially mitigate this loss based on general caloric restriction literature, but no semaglutide-specific resistance training trial has confirmed it.^[10] This remains the single largest evidence gap relevant to the enhancement community.

Weight regain after discontinuation is rapid and well-documented.^[4] Any physique application must account for this. A structured transition plan is non-negotiable when discontinuing treatment.

The cardiovascular safety profile is favorable — particularly relevant for people managing cardiovascular load from other compounds. The 20% MACE reduction observed in SELECT is meaningful risk reduction, though it was shown in a different population than the typical enhancement user.^[7]

Semaglutide works. Whether it is the right tool depends entirely on individual goals, current body composition, concurrent pharmacology, and willingness to either maintain treatment long-term or carefully manage the discontinuation transition.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
2. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021;325(14):1403-1413. PubMed
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414-1425. PubMed
5. Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PubMed
6. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA. 2022;327(2):138-150. PubMed
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PubMed
9. Lundgren JR, Janus C, Jensen SBK, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730. PubMed
10. Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017;8(3):511-519. PubMed
11. Ida S, Kaneko R, Imataka K, et al. Effects of Anti-diabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus. Curr Diabetes Rev. 2021;17(3):293-303. PubMed
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340. PubMed
13. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed
14. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664-1675. PubMed
15. Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. PubMed
16. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PubMed
17. Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism. 2019;92:170-192. PubMed

Frequently Asked Questions